The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment sequencing after adjuvant treatment failure in patients with melanoma: A retrospective cohort study.
 
Konstantinos Lallas
No Relationships to Disclose
 
Teresa Amaral
Consulting or Advisory Role - Delcath Systems; Medscape; Menarini; NeraCare GmbH; Novartis; Philogen; Pierre Fabre
Research Funding - Agenus (Inst); AstraZeneca (Inst); BioNTech SE (Inst); Biotech IOB (Inst); BMS GmbH & Co. KG (Inst); HUYA Bioscience International (Inst); Immunocore (Inst); MSD (Inst); NeraCare GmbH (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Regeneron (Inst); Replimune (Inst); Roche/Genentech (Inst); Sanofi Aventis GmbH (Inst); Skyline Diagnostics (Inst)
Patents, Royalties, Other Intellectual Property - 18/384,708 ErbB-MEL ("EGFR")
Travel, Accommodations, Expenses - NeraCare GmbH; Skyline Diagnostics
 
Eftychia Chatziioannou
No Relationships to Disclose
 
Andreas Meiwes
No Relationships to Disclose
 
Francisco Meraz Torres
No Relationships to Disclose
 
Joana Schroth
No Relationships to Disclose
 
Alexandra Guedes
No Relationships to Disclose
 
Zoe Apalla
No Relationships to Disclose
 
Aimilios Lallas
No Relationships to Disclose
 
Lukas Flatz
Honoraria - from BMS, MSD, Novartis, Pierre Fabre, Sanofi, Regeneron and Sunpharma
Travel, Accommodations, Expenses - MSD, BMS, Pierre Fabre, Sanofi, Sunpharma and Novartis
 
Lena Nanz
No Relationships to Disclose
 
Ulrike Leiter
Consulting or Advisory Role - Merck Sharp & Dohme, Novartis, Regeneron, Sanofi, Sun Pharma, Almirall Hermal and Pierre Fabre
Research Funding - Merck Sharp & Dohme
Travel, Accommodations, Expenses - Pierre Fabre, and Sun Pharma